Trimtech Therapeutics Secures $31M Seed Funding for CNS Treatments

Trimtech Therapeutics, a biotech startup focused on treating neurodegenerative diseases, has successfully raised $31 million in seed funding, primarily led by Cambridge Innovation Capital (CIC) and SV Health Investors' Dementia Discovery Fund (DDF). The funds will be utilized to develop its TRIMTAC platform, which employs targeted protein degradation (TPD) to address conditions such as Alzheimer’s and Huntington’s disease. This innovative approach leverages the E3 ubiquitin ligase TRIM21 to selectively degrade harmful protein aggregates, potentially transforming treatment for millions of affected patients. The round also attracted investments from notable firms including Pfizer Ventures and Eli Lilly, reflecting strong confidence in Trimtech’s scientific foundations and leadership team. Founded by CIC and DDF along with key academic partners, Trimtech has also expanded its board with experienced life science executives. CEO Nicola Thompson highlighted the round's success as a testament to the company's unique approach and potential in the biotech landscape.